Mark Lebwohl, MD - Apremilast as an Off-Label Therapeutic Agent

Psoriasis: Which Drug for Which Patient? Mark Lebwohl, MDПодробнее

Dr. Mark Lebwohl, 2021 American Skin Association Research Achievement AwardПодробнее

Commit to Cure: Dr. Mark Lebwohl TributeПодробнее

FC21 - Ustekinumab and IL-23 Blockers, Mark Lebwohl, MDПодробнее

Which Psoriasis Therapy for Which PatientПодробнее

Superior risankizumab efficacy vs. apremilast in systemic-eligible moderate psoriasis.Подробнее

WCH23: What’s New and Hot in Biologic TherapyПодробнее

Digital Highlights Hub | Dr Mark Lebwohl, MDПодробнее

Mark Lebwohl, MD, FAAD - Frontiers In Academic Pathology 2015Подробнее

Mark Lebwohl, MD - Who is topical roflumilast approved for?Подробнее

The Newest in Dermatology: Acne, Atopic Dermatitis, Actinic Keratosis, Psoriasis, and Skin CancerПодробнее

1 Mark Lebwohl, MD, FAADПодробнее

Episode 12 - Zinc Oxide in Sunscreens; and a chat with Dr Mark LebwohlПодробнее

Mark Lebwohl, MD - What is the overall tolerability and most common side effects of roflumilast?Подробнее

Mark Lebwohl, MD - What is topical roflumilast?Подробнее

DermTV - Psoriasis 101 with Dr. Mark Lebwohl [DermTV.com Epi #384]Подробнее

Psoriasis Posters and Abstracts from Orlando: Module 2Подробнее

WHAT'S NEW : NEWER INDICATIONS FOR APREMILASTПодробнее

Mark Lebwohl, MD - How does treatment with roflumilast differ from treatment with topical steroids?Подробнее